📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

IL-1 Signal Inhibition In Alcoholic Hepatitis (ISAIAH): a study protocol for a multicentre, randomised, placebo-controlled trial to explore the potential benefits of canakinumab in the treatment of alcoholic hepatitis. (2021)

First Author: Vergis N

Attributed to: MICA: Minimising Mortality from Alcoholic Hepatitis funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1186/s13063-021-05719-2

PubMed Identifier: 34763711

Publication URI: http://europepmc.org/abstract/MED/34763711

Type: Journal Article/Review

Volume: 22

Parent Publication: Trials

Issue: 1

ISSN: 1745-6215